BioSpace News Archive

SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, today announced the results from the first every application of the Selective Cytopheretic Device (SCD) in pediatric patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT).

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Zomedica Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders. Dear Shareholders: I am writing to you today with a single, straightforward message -- please vote for the domestication proposal described in our proxy materials for our virtual Special Meeting to be held on December 15, 2020. Approval of the domestication proposal wi

- BI-1808 is a novel mechanism of action antibody discovered through BioInvent’s unique proprietary F.I.R.S.T™ technology platform - BI-1808 to be evaluated as monotherapy and in combination with anti-PD-1 antibody, Keytruda® - The first patients expected to be enrolled before year-end

As North America continues to battle the COVID-19 pandemic, reopening the economy intensifies the need for a safe medical-grade PPE solution that is cost-efficient, readily available, and comfortable while alleviating waste sent to landfills

T-cells taken from the blood of people who recovered from a COVID-19 infection can be successfully multiplied in the lab and maintain the ability to effectively target proteins that are key to the virus’s function, according to a new study published Oct. 26 in Blood.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is

Despite the increasing use and promise of hematopoietic cell transplantation (HCT) as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children transplanted for cancer are more likely to die from treatment-related complications if they live in poorer neighborhoods.

AscellaHealth, a national specialty pharmacy benefit manager (SPBMTM) serving commercial, Medicare and Medicaid segments, announces today that it has won the prestigious Philadelphia100 award as 7th among 100 of the fastest growing privately held entrepreneurial companies in the Greater Philadelphia Region.

Additional Sample Collection for Validation Study Hindered due to COVID-19 Infection Rate Increase, Causes Delay in Sales Launch